BioAge Labs Expands APJ Agonist Pipeline
BioAge Labs, Inc. is making significant strides in the development of therapeutic candidates targeting metabolic diseases, particularly by harnessing the power of the apelin receptor (APJ). This innovative company, based in Emeryville, has recently announced an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody.
Advancements in APJ Agonists
As a part of its ongoing effort to combat obesity and related metabolic disorders, BioAge is advancing its pipeline of orally active and highly potent small molecule APJ agonists. The company has recently filed for a provisional patent that covers chemically distinct APJ agonists, pointing to their commitment to developing high-potency therapeutic options.
The Role of Apelin
Apelin is recognized for its role as an exercise-induced signaling molecule, which is vital for maintaining physical health and longevity. BioAge’s research data highlight a strong link between higher circulating levels of apelin and better physical function. In preclinical trials, the effects of APJ agonism have demonstrated a significant enhancement of weight loss outcomes, doubling the effectiveness of existing GLP-1 receptor therapies while improving overall body composition and muscle strength.
Strategic Collaboration with JiKang
The collaboration with JiKang Therapeutics is pivotal for BioAge's mission. JiKang specializes in the development of biologics that interact with G protein-coupled receptors (GPCRs), with their APJ-agonist nanobody showing great promise. This nanobody is reportedly more potent than the natural ligand of APJ, making it a leading candidate for future metabolic disease therapies.
Joint Development Plans
Under the terms of the licensing option with JiKang, both companies will work together to bring the APJ agonist nanobody to the IND-enablement phase. If BioAge exercises this option, it will take the helm of global development and commercialization, reinforcing its leadership in the field. JiKang will not only receive an initial funding boost but will also have the chance to benefit from tiered royalties as the project advances.
Innovative Small Molecule Program
In addition to the collaboration with JiKang, BioAge is propelling its internal small molecule APJ agonist program. The recent patent filing emphasizes their focus on creating a new class of orally active apelin receptor agonists that balance potency with necessary drug-like properties, such as stability and pharmacokinetics. The innovative design of these compounds was facilitated through advanced computational modeling techniques and AI technology.
Future Prospects for BGE-102
Beyond just APJ agonists, BioAge is working diligently on its lead product candidate, BGE-102, which functions as a small-molecule NLRP3 inhibitor. Designed for obesity treatments, BGE-102 has shown robust weight loss in early-stage trials and is poised for IND submission, with plans for initiating clinical trials soon.
About BioAge Labs
BioAge Labs operates at the intersection of biotechnology and longevity science, dedicated to creating treatments that address the aging process and its associated diseases. With a robust candidate lineup and a pipeline bolstered by research into human longevity, BioAge aims to set new standards in metabolic disorder therapy.
Company Contact Information
If you would like to reach BioAge for inquiries, please contact:
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Frequently Asked Questions
What is BioAge Labs focused on developing?
BioAge Labs, Inc. is dedicated to creating therapeutic candidates for metabolic diseases by targeting the biology of human aging.
What significant agreement did BioAge recently enter?
BioAge entered an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody.
How does apelin relate to metabolic health?
Apelin is a signaling molecule linked to exercise that has shown beneficial effects on weight loss and physical function in preclinical studies.
What is the goal for BioAge's APJ agonist program?
The goal is to submit an Investigational New Drug (IND) application for an APJ agonist by 2026.
What can we expect from BioAge Labs in the near future?
BioAge is expected to advance new metabolic disease treatments, including novel drug candidates that enhance weight loss and overall health.
